Analysts Rating Network 11/10/13 Facebook ( FB )
Facebook Company Profile (NASDAQ:FB)
Share on StockTwits
Analyst Rating Network 11/10/13 Facebook ( FB )
Analysts' Ratings History for Facebook (NASDAQ:FB)
Date Firm Action Company New Rating New Price Target Details
11/1/2013 Deutsche Bank Facebook Inc. (FB) Buy $62.00
11/1/2013 Argus Upgrade Facebook Inc. (FB) Buy $63.00 View
10/31/2013 Canaccord Genuity Boost Price Target Facebook Inc. (FB) Buy $62.00 View
10/31/2013 Oppenheimer Boost Price Target Facebook Inc. (FB) Outperform $60.00 View
10/31/2013 JPMorgan Chase & Co. Boost Price Target Facebook Inc. (FB) Overweight $62.00 View
10/31/2013 UBS AG Boost Price Target Facebook Inc. (FB) Buy $62.00 View
10/31/2013 Raymond James Reiterated Rating Facebook Inc. (FB) Outperform $60.00 View
10/31/2013 Wells Fargo & Co. Reiterated Rating Facebook Inc. (FB) Outperform $61.00 View
10/31/2013 Cantor Fitzgerald Boost Price Target Facebook Inc. (FB) Buy $63.00 View
10/31/2013 Topeka Capital Markets Reiterated Rating Facebook Inc. (FB) Buy $63.00 View
know when to cover.
big upgrades after earnings $
FDA Approves Drug for Rare Blood Cancer
Wall Street Journal
By ANNA PRIOR CONNECT
Nov. 13, 2013 2:17 p.m. ET
Pharmacyclics Inc. PCYC +2.05% said the U.S. Food and Drug Administration has approved a drug to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.
Imbruvica, or ibrutinib, which is co-marketed by the Sunnyvale, Calif.-based pharmaceutical company and Johnson & Johnson JNJ -0.37% unit Janssen Biotech Inc., is the second drug to be approved by the FDA via the breakthrough therapy designation pathway, a designation earned if preliminary clinical evidence indicates the drug may offer a substantial improvement over available therapies for patients with serious or life-threatening diseases, the FDA said.
The FDA's approval was based on the results of a trial of 111 patients with previously treated mantle cell lymphoma, with the efficacy results demonstrating a 65.8% overall response rate, Pharmacyclics said.
The company also noted Imbruvica is commercially available worldwide and immediately.
Pharmacyclics and Janssen entered a collaboration in December 2011 to develop and commercialize an oral treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
Fox Business News 9/9/13
Here Are the Top 5 Social Networks in the U.S.
Jacqueline Sahagian Google+ Twitter | More Articles
October 02, 2013
Page 5 of 5
Fifty-seven percent of the poll’s respondents reported having a Facebook account, making it the clear front runner in social networking sites used in the U.S., which comes as no surprise. Among respondents aged 18 to 24, 89 percent reported having a Facebook account. That age group showed the heaviest social media usage for every site except LinkedIn. Several other recent studies have backed up Kantar’s findings that Facebook completely dominates the social media spectrum, and is cashing in big time with both desktop and mobile ads.
Facebook Inc (NASDAQ:FB): More good news for the recently-surging stock, today begun with a Buy recommendation and $52 price objective at CRT Capital. The broker says mobile ad revenue is now at a runrate of over $3.6 billion.
China To Allow Facebook, Twitter In Shanghai Free Trade Zone – An Empty Gesture
By Shuli Ren
All across the China-related media today is a story from South China Morning Post that the new Shanghai Free Trade Zone will allow users to access banned western social media platforms Facebook (FB) and Twitter, and allow foreign telecoms to operate there:
haha hope u bought.
Facebook price target upped to $62 by Macquarie
SAN FRANCISCO (MarketWatch) - Macquarie on Thursday raised its price target for Facebook Inc. FB -2.11% to $62 from $49, based on the social network's momentum in mobile ads. "Facebook continues to gain traction with its efforts to monetize the mobile user base, with new statistics on mobile app install ads suggesting that growth remains strong and could generate upside to mobile ad revenue for the third quarter," analyst Ben Schachter said in a note